Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Tita-Nwa, Dinga Nkom Freddy [VerfasserIn]   i
 Moldenhauer, Gerhard [VerfasserIn]   i
 Herbst, Markus [VerfasserIn]   i
 Kleist, Christian [VerfasserIn]   i
 Ho, Anthony Dick [VerfasserIn]   i
 Kornacker, Martin [VerfasserIn]   i
Titel:Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells
Verf.angabe:Freddy Tita-Nwa, Gerhard Moldenhauer, Markus Herbst, Christian Kleist, Anthony D. Ho, Martin Kornacker
E-Jahr:2007
Jahr:9 May 2007
Umfang:10 S.
Illustrationen:Illustrationen
Teil:volume:56
 year:2007
 number:12
 pages:1911-1920
 extent:10
Fussnoten:Gesehen am 20.10.2021
Titel Quelle:Enthalten in: Cancer immunology immunotherapy
Ort Quelle:Berlin : Springer, 1976
Jahr Quelle:2007
Band/Heft Quelle:56(2007), 12, Seite 1911-1920
ISSN Quelle:1432-0851
Abstract:Due to their dual binding capacity, bispecific antibodies (bsAb) can be used to cross-link cytotoxic effector cells with malignant targets and may thereby improve adoptive immunotherapy. In this study, the development and preclinical testing of the quadroma-derived bsAb HD37xT5.16 of the specificity CD19xCD5 is reported. Effector cells used were a population of ex vivo expanded and activated T cells called cytokine-induced killer (CIK) cells expressing CD5. When combined with CIK cells, the cytolytic potency of HD37xT5.16 against CD19 positive B cell lymphoma lines was comparable to that observed with a previously described CD19xCD3 bsAb. Further on, we could demonstrate that bsAb CD19xCD5, in contrast to its CD3-binding counterpart, does not induce proliferation of resting T cells and causes only little activation-induced cell death. Therefore, this novel bsAb binding effector T cells via CD5 may be particularly useful in combination with adoptive transfer of ex vivo activated T cells, e.g., in the setting of adoptive immunotherapy after allogeneic stem cell transplantation. The in vitro studies outlined here support the experimental use of bsAb HD37xT5.16 in preclinical in vivo models for evaluation of its safety and efficacy profile.
DOI:doi:10.1007/s00262-007-0333-0
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1007/s00262-007-0333-0
 DOI: https://doi.org/10.1007/s00262-007-0333-0
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1774597969
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68791927   QR-Code
zum Seitenanfang